Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2023-08-14 00:00:00 ET · period of report 2023-08-10 · accession 0001714899-23-000123 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2023-08-14 | 2023-08-10 | DNLI | Watts Ryan J. | Pres, CEO, Dir | M - OptEx | $0.68 | +2,526 | 2.24M | +0.1% | +$1,718 |
| DI | 2023-08-14 | 2023-08-10 | DNLI | Watts Ryan J. | Pres, CEO, Dir | S - Sale+OE | $25.03 | -2,526 | 2.24M | -0.1% | -$63.2K |
| D | 2023-08-14 | 2023-08-10 | DNLI | Watts Ryan J. | Pres, CEO, Dir | M - OptEx | $0.00 | -2,526 | 1.12M | -0.2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-10 | M | A | 2,526 | $0.68 | 2,242,439 | I See footnote | — | — | (F1) Exercised shares were issued to the Watts Family 2015 Trust. (F2) The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. |
| 2 | Common | Common Stock | 2023-08-10 | S | D | 2,526 | $25.03 | 2,239,913 | I See footnote | — | — | (F4) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F2) The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. |
| 3 | Derivative | Stock Option (right to buy) | 2023-08-10 | M | D | 2,526 | $0.00 | 1,118,091 | D | $0.68 · — to 2025-08-20 | 2,526 Common Stock | (F6) The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. |